1.123EUR-2.43%Mkt Cap: 793.47M EURP/E: 56.17Last update: 2026-06-01
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. Th…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap793.47M EUR
Enterprise Value803.57M EUR
Revenue (TTM)369.49M EUR
Gross Profit330.63M EUR
Net Income (TTM)2.85M EUR
Revenue/Share0.5220 EUR
Last Price1.123 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees407
CountryNL
SectorHealthcare
IndustryBiotechnology
ISINNL0010391025
Valuation
P/E (Trailing)56.17
P/E (Forward)37.05
PEG—
EV/EBITDA19.00
EV/Revenue2.17
P/S2.20
P/B3.42
EPS (TTM)0.02
EPS (Forward)0.03
52W Range
0.838029% of range1.818
52W High1.818 EUR
52W Low0.8380 EUR
Profitability
Gross Margin87.90%
Oper. Margin-6.78%
EBITDA Margin11.44%
Profit Margin0.76%
ROE1.03%
ROA0.57%
Growth
Revenue Growth-8.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF54.71M EUR
CapEx (TTM)755.00K EUR
FCF Margin15.97%
FCF Yield7.44%
Net Debt-53.97M EUR
Net Debt/EBITDA-1.28
Balance Sheet
Debt/Equity0.42
Current Ratio2.63
Quick Ratio2.05
Book Value/Sh0.3370 EUR
Cash/Share0.2290 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateMar 5, 2013
Analyst Consensus
Rating—
Target (Mean)2.226 EUR
Target Range1.896 EUR – 2.608 EUR
# Analysts4
Ownership
Shares Out.706.25M
Float733.15M
Insiders1.72%
Institutions24.54%
Technical
SMA 501.337 (-16.0%)
SMA 2001.356 (-17.1%)
Beta0.12
S&P 52W Chg27.94%
Avg Vol (30d)11.55M
Avg Vol (10d)9.10M
Technical Indicators
RSI (14)39.7
MACD-0.0520
MACD Signal-0.0657
MACD Hist.+0.0137
BB Upper1.388 EUR
BB Middle1.168 EUR
BB Lower0.9474 EUR
BB Width37.76%
ATR (14)0.0507 EUR
Vol Ratio (20d)0.79x